High-dose folinic acid and 5-fluorouracil bolus and continuous infusion in advanced colorectal cancer
| Autor: | J.E. Maisani, B. Demuynck, Jean Cady, Jean-Didier Grange, Jacques Debray, Jean-Philippe Loiseau, Jacques Seroka, B. Lagadec, Marcel Krulik, Christophe Louvet, Dray C, G. Gonzalez-Canali, Aimery de Gramont |
|---|---|
| Rok vydání: | 1988 |
| Předmět: |
Adult
Male medicine.medical_specialty Colorectal cancer medicine.drug_class medicine.medical_treatment Leucovorin Adenocarcinoma Antimetabolite Gastroenterology Folinic acid Bolus (medicine) Internal medicine Antineoplastic Combined Chemotherapy Protocols Humans Medicine Prospective Studies Aged Chemotherapy business.industry Middle Aged Prognosis medicine.disease Carcinoembryonic Antigen Oncology Fluorouracil Anesthesia Toxicity Female Colorectal Neoplasms business Progressive disease medicine.drug |
| Zdroj: | European Journal of Cancer and Clinical Oncology. 24:1499-1503 |
| ISSN: | 0277-5379 |
| DOI: | 10.1016/0277-5379(88)90341-0 |
| Popis: | An enhanced antineoplastic effect of 5-fluorouracil in patients with advanced colorectal cancer has been produced either by combination with folinic acid or administration by continuous infusion. Thirty-seven patients with advanced measurable colorectal cancer received high-dose folinic acid (LV 200 mg/m2) followed by 5-fluorouracil i.v. bolus (300 mg/m2) and continuous infusion (300 mg/m2) on days 1 and 2 then 14 and 15 every 4 weeks. In the absence of toxicity, 5-FU was increased to 400 mg/m2 i.v. bolus and continuous infusion at course 2 and to 500 mg/m2 at course 3 and from course 4 maintained at 500 mg/m2. Responses were: complete responses: 1 (2.7%), partial responses: 19 (51.4%), no change: 8 (21.6%) and progressive disease: 9 (24.3%). CEA decrease was correlated with response. Median duration of response was 11 months. Median survival was 18 months, 21% of the patients were alive at 2 years. Toxicity was low, with diarrhea in 17% and nausea in 11.5% of the patients. LV-5-FU bolus and continuous infusion is safe and has definite activity in metastatic colorectal cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|